Managing Director, Access Biotechnology
CurrentBiopharma investing in private and public companies across therapeutic areas, modalities, and development stages. Representative private investments include Nimbus Therapeutics (Tyk2 subsidiary acq. by Takeda for up to $6 billion incl. $4 billion upfront), Hemab, Areteia Therapeutics, Perfuse Therapeutics, and Matchpoint Therapeuticswww.accessbiotech.com